Report topline OLE and PK run-in study data

Delivered by the deadline

AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.

Announced: 24 Mar 2025
Due: 30 Sep 2025
Delivered: September 2025

Deadline
Met
Late
Not met
Today

What the company said

“Larimar plans to provide an update on OLE data on at least 30 to 40 study participants... in September 2025”

SourceLarimar Therapeutics, Inc. Form 8-K press release, 2025-03-24
FilingSEC filing index
Deadline as statedSeptember 2025
Deadline used30 Sep 2025, the last day of the stated period
TypeProject
Permanent referenceKI-C-2025-LRMR-003032
Cite as https://keptindex.org/c/KI-C-2025-LRMR-003032/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced data from its ongoing long-term open label study in September 2025, fulfilling the commitment to report topline data.

A
Larimar Therapeutics, Inc. 10-Q filed 2025-11-05 Regulatory filing · published 5 Nov 2025 · retrieved 1 Oct 2026 · kept permanently by the SEC
“In September 2025, the Company announced data from its ongoing long-term open label study” ✓ confirmed on the page
A
Larimar Therapeutics, Inc. 10-K filed 2026-03-19 Regulatory filing · published 19 Mar 2026 · retrieved 1 Oct 2026 · kept permanently by the SEC
“Note: Data presented is based on the September 2025 data release.” ✓ confirmed on the page

Market reaction: the shares moved -8.3% against the S&P 500 over the three sessions around the disclosure (4 Nov 2025 to 7 Nov 2025). What this measures

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

2 versions

Version 1 · original · stated 24 Mar 2025

Deadline 30 Sep 2025 (“September 2025”) · target 30 participants · wording expected
Version 2 · stated 30 Apr 2025

Deadline 30 Sep 2025 (“in September 2025”) · target 50 mg · wording expected

“topline 50 mg dose data from the OLE study and data from adolescent cohort planned for program update in September 2025”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: OLE and PK run-in study data
Target: 30 participants
Language: Expected (“expects”, “plans”)
In the company’s control: High
Specificity: High

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Larimar Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.